Business Wire

Veristat Strengthens Its Regulatory Expertise with the Acquisition of Catalyst Regulatory Services

16.12.2019 17:26:00 EET | Business Wire | Press release

Share

Veristat, a full-service CRO, announced today that it has completed the acquisition of Catalyst Regulatory Services, LLC., a US-based regulatory services company. Catalyst provides comprehensive regulatory support to biopharmaceutical firms as they obtain and maintain their regulatory applications along the pathway to market approval.

“With the addition of Catalyst, Veristat has amassed a superior team of regulatory experts to offer strategic and operational regulatory support throughout all phases of drug, biologic, and medical device development,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “We continue to expand and strengthen our regulatory offering to support the growing demand for our experience and insights with regulators. Our regulatory solutions make an impact – in 2018 alone – Veristat teams prepared marketing applications for 12% of New Molecular Entities (NMEs) approved by the FDA.”

Helping sponsors develop and pursue the right regulatory pathway for their clinical program requires years of experience, expertise with agency interactions and a proven history of success. That is why Veristat acquired Catalyst Regulatory Services. This combination creates a unique and unmatched team of senior regulatory experts who develop and implement regulatory strategies, applications, submissions, and interactions with regulatory agencies around the globe.

As part of the acquisition, Veristat appoints Mark Ammann, Pharm.D., former President of Catalyst Regulatory Services, LLC., to the role of Senior Vice President, Regulatory Affairs, where he will lead the regulatory affairs team. Mark is a recognized leader in the regulatory affairs community with extensive knowledge of regulatory challenges throughout the clinical development process. His 25+ years of experience include positions in both Big Pharma and service organizations. The therapeutic expertise of Mark and the broader Catalyst team augment and expand the oncology, rare disease, neurological and anti-infection depth of Veristat today by increasing our experience in numerous therapy areas including Cardiovascular Disease, Psychiatry, Neurology, Diabetes, Metabolic Disorders, Inflammation, Oncology, Dermatology, and Nephrology.

“We are excited to join the Veristat team,” said, Mark Ammann, Pharm.D., now Senior Vice President, Regulatory Affairs at Veristat, “The combination of Catalyst Regulatory Services and Veristat creates a diverse regulatory talent pool that can provide comprehensive regulatory support including regulatory CMC, labeling, advertising/promotion, and FDA meeting preparation and agency engagement. Together, we support a wide range of products, from traditional small molecules and simple biologics to combination products, as well as more complex approaches including antibody-drug complexes, and cellular and gene therapies.”

About Veristat

Veristat is a scientifically oriented and impactful full-service clinical research organization (CRO) that is committed to partnering with pharmaceutical, biotechnology, and medical device firms to advance their therapies throughout the entire clinical development and regulatory submission process. Veristat helps clients solve the unique and complex challenges that arise when trying to accelerate therapies along the development pathway to successful regulatory approval, beginning with study design, protocol development, site selection, and start-up through to clinical monitoring, data collection, analysis, and reporting. Veristat provides experience-based strategic decision-making, the operational efficiencies to manage and monitor international trials, the biometrics expertise to collect, analyze and report clinical trial data to various regulatory agencies, and the therapeutic and medical proficiency in overseeing the entire process. Ultimately, we guide our clients to market success so that their therapies become available to improve and save people’s lives. In 2018, a record-setting year of FDA approvals Veristat supported the marketing applications for 12% of all FDA NME approvals. For more information, visit http://www.veristat.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat Contact:
Gillian Dellacioppa, Marketing Director
gillian.dellacioppa@veristat.com or +1 508-306-6336

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 08:30:00 EET | Press release

Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol

Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 03:30:00 EET | Press release

Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for the first time reflects both the strength of India's technology ecosystem and the growing role its enterprises play in shaping global supply chai

Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 23:30:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and

Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 23:00:00 EET | Press release

Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin

Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 23:00:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye